BRIEF-Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)

Reuters12-14

BRIEF-Checkpoint <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)

Dec 13 (Reuters) - Checkpoint Therapeutics Inc CKPT.O:

CHECKPOINT THERAPEUTICS ANNOUNCES FDA APPROVAL OF UNLOXCYT™ (COSIBELIMAB-IPDL)

Source text: nGNX3Mnqk6

Further company coverage: CKPT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491828785?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 07:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491828785","market":"us","top_or_hot":-1,"title":"BRIEF-Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Checkpoint <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)</title></head><body><p><span>Dec 13 (Reuters)</span><span> - </span>Checkpoint Therapeutics Inc <span>CKPT.O</span>:</p><ul><li><p>CHECKPOINT THERAPEUTICS ANNOUNCES FDA APPROVAL OF UNLOXCYT™ (COSIBELIMAB-IPDL)</p></li></ul><p>Source text: <span>nGNX3Mnqk6</span></p><p>Further company coverage: <span>CKPT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-14 07:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUA2K6LJS:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)Dec 13 (Reuters) - Checkpoint Therapeutics Inc CKPT.O:CHECKPOINT THERAPEUTICS ANNOUNCES FDA APPROVAL OF UNLOXCYT™ (...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUA2K6LJS:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CKPT","symbol_name":"Checkpoint Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUA2K6LJS:1","article_id":"2491828785","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491828785","pubTimestamp":1734131825,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Checkpoint Therapeutics Announces FDA Approval Of UnloxcytDec 13  - Checkpoint Therapeutics Inc CKPT.O:CHECKPOINT THERAPEUTICS ANNOUNCES FDA APPROVAL OF UNLOXCYT Source text: nGNX3Mnqk6Further company coverage: CKPT.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CKPT":"Checkpoint Therapeutics, Inc.","BK4139":"生物科技","FBIO":"Fortress Biotech Inc."},"translate_title":"简报-Checkpoint Therapeutics宣布FDA批准Unloxcyt(Cosibelimab-Ipdl)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CKPT":0.9,"FBIO":0.9},"content_text":"BRIEF-Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)Dec 13 (Reuters) - Checkpoint Therapeutics Inc CKPT.O:CHECKPOINT THERAPEUTICS ANNOUNCES FDA APPROVAL OF UNLOXCYT™ (COSIBELIMAB-IPDL)Source text: nGNX3Mnqk6Further company coverage: CKPT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491828785"}